Skip to main content
Top
Published in: Tumor Biology 8/2015

01-08-2015 | Research Article

Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells

Authors: Biao Wang, Shuo Li, Xin Meng, Hong Shang, Yifu Guan

Published in: Tumor Biology | Issue 8/2015

Login to get access

Abstract

The expression of ATP-dependent efflux pump P-glycoprotein (P-gp) in cancer cells generally results in multidrug resistance (MDR) to chemotherapeutic drugs, which is the main cause of chemotherapy failure in cancer treatment. The intracellular drug levels could be increased by some MDR reversal agents that inhibited the drug efflux activity of P-gp. The synthesized DNA nucleic acids of G-quadruplex represent a novel and unique class of anti-cancer agents. While there was no report on the roles of DNA G-quadruplex oligonucleotides (GQ-ODNs) in the MDR reversal, the present study was performed to investigate the ability of synthesized GQ-ODNs to reverse P-gp-mediated MDR and its mechanism in paclitaxel (PTX)-resistant SKOV3 (SKOV3/PTX) cells and their sensitive cell lines SKOV3. The ability of GQ-ODNs to reverse drug resistance was evaluated by MTS assay. The results showed that GQ-ODNs can reverse PTX resistance effectively. The potential of GQ-ODNs as reversal agents was evaluated with the nude mice tumor xenograft model and showed that the co-administration of the GQ-ODNs and PTX had better effects and was also more evident than treatment with only PTX. The P-gp expression was assessed by the Western blot; it showed that SKOV3/PTX cells showed highly expressed P-gp protein, while their sensitive cells scarcely showed P-gp. The presence of GQ-ODNs efficiently decreased the P-gp expression, showing that GQ-ODNs could reverse P-gp-mediated MDR by decreasing the expression of P-gp. This study indicated that GQ-ODNs could effectively reverse P-gp-mediated PTX resistance by inhibiting the expression of P-gp and by the co-administration of GQ-ODNs and PTX that could increase the apoptosis of SKOV3/PTX cells. Thus, the synthesized GQ-ODNs may be a potential inhibitor to overcome drug resistance.
Literature
1.
go back to reference Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(7):2054–60.CrossRef Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(7):2054–60.CrossRef
2.
go back to reference McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.CrossRefPubMed McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6.CrossRefPubMed
3.
go back to reference Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107(1):118–23.CrossRefPubMed Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol Oncol. 2007;107(1):118–23.CrossRefPubMed
4.
go back to reference Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.CrossRefPubMed Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1–19.CrossRefPubMed
5.
go back to reference Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr. 1993;15:55–61.
6.
go back to reference Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990;50(6):1748–56.PubMed Ford JM, Bruggemann EP, Pastan I, Gottesman MM, Hait WN. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines. Cancer Res. 1990;50(6):1748–56.PubMed
7.
go back to reference Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem. 1994;31:1–61.CrossRefPubMed Bellamy WT, Dalton WS. Multidrug resistance in the laboratory and clinic. Adv Clin Chem. 1994;31:1–61.CrossRefPubMed
8.
go back to reference Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002;86(3):302–10.CrossRefPubMed Seiden MV, Swenerton KD, Matulonis U, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002;86(3):302–10.CrossRefPubMed
9.
go back to reference Webba da Silva M. Geometric formalism for DNA quadruplex folding. Chemistry. 2007;13(35):9738–45.CrossRefPubMed Webba da Silva M. Geometric formalism for DNA quadruplex folding. Chemistry. 2007;13(35):9738–45.CrossRefPubMed
10.
go back to reference Huppert JL. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem Soc Rev. 2008;37(7):1375–84.CrossRefPubMed Huppert JL. Four-stranded nucleic acids: structure, function and targeting of G-quadruplexes. Chem Soc Rev. 2008;37(7):1375–84.CrossRefPubMed
12.
go back to reference Agarwal T, Jayaraj G, Pandey SP, Agarwala P, Maiti S. RNA G-quadruplexes: G-quadruplexes with “U” turns. Curr Pharm Des. 2012;18(14):2102–11.CrossRefPubMed Agarwal T, Jayaraj G, Pandey SP, Agarwala P, Maiti S. RNA G-quadruplexes: G-quadruplexes with “U” turns. Curr Pharm Des. 2012;18(14):2102–11.CrossRefPubMed
14.
15.
go back to reference Chaires JB. Human telomeric G-quadruplex: thermodynamic and kinetic studies of telomeric quadruplex stability. FEBS J. 2010;277(5):1098–106.CrossRefPubMed Chaires JB. Human telomeric G-quadruplex: thermodynamic and kinetic studies of telomeric quadruplex stability. FEBS J. 2010;277(5):1098–106.CrossRefPubMed
16.
go back to reference Goodchild A, King A, Gozar MM, Passioura T, Tucker C, Rivory L. Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 2007;35(13):4562–72.CrossRefPubMedPubMedCentral Goodchild A, King A, Gozar MM, Passioura T, Tucker C, Rivory L. Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Res. 2007;35(13):4562–72.CrossRefPubMedPubMedCentral
17.
go back to reference Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004;64(18):6603–9.CrossRefPubMed Jing N, Li Y, Xiong W, Sha W, Jing L, Tweardy DJ. G-quartet oligonucleotides: a new class of signal transducer and activator of transcription 3 inhibitors that suppresses growth of prostate and breast tumors through induction of apoptosis. Cancer Res. 2004;64(18):6603–9.CrossRefPubMed
18.
go back to reference Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther. 2006;5(2):279–86.CrossRefPubMed Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther. 2006;5(2):279–86.CrossRefPubMed
19.
go back to reference Pedersen EB, Nielsen JT, Nielsen C, Filichev VV. Enhanced anti-HIV-1 activity of G-quadruplexes comprising locked nucleic acids and intercalating nucleic acids. Nucleic Acids Res. 2011;39(6):2470–81.CrossRefPubMed Pedersen EB, Nielsen JT, Nielsen C, Filichev VV. Enhanced anti-HIV-1 activity of G-quadruplexes comprising locked nucleic acids and intercalating nucleic acids. Nucleic Acids Res. 2011;39(6):2470–81.CrossRefPubMed
20.
go back to reference Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem. 1998;273(52):34992–9.CrossRefPubMed Jing N, Hogan ME. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J Biol Chem. 1998;273(52):34992–9.CrossRefPubMed
21.
go back to reference Zhi L, Zhang J, Jia Y, et al. Effect of G-rich oligonucleotides on the proliferation of leukemia cells and its relationship with p53 expression. Oligonucleotides. 2011;21(1):21–7.CrossRefPubMed Zhi L, Zhang J, Jia Y, et al. Effect of G-rich oligonucleotides on the proliferation of leukemia cells and its relationship with p53 expression. Oligonucleotides. 2011;21(1):21–7.CrossRefPubMed
22.
go back to reference Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem. 2001;276(46):43221–30.CrossRefPubMed Xu X, Hamhouyia F, Thomas SD, et al. Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. J Biol Chem. 2001;276(46):43221–30.CrossRefPubMed
23.
go back to reference Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–64.CrossRefPubMedPubMedCentral Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol. 2009;86(3):151–64.CrossRefPubMedPubMedCentral
24.
go back to reference Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol. 2007;31(1):129–36.PubMed Weerasinghe P, Garcia GE, Zhu Q, et al. Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int J Oncol. 2007;31(1):129–36.PubMed
25.
go back to reference Scaggiante B, Dapas B, Grassi G, Manzini G. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J. 2006;273(7):1350–61.CrossRefPubMed Scaggiante B, Dapas B, Grassi G, Manzini G. Interaction of G-rich GT oligonucleotides with nuclear-associated eEF1A is correlated with their antiproliferative effect in haematopoietic human cancer cell lines. FEBS J. 2006;273(7):1350–61.CrossRefPubMed
26.
go back to reference Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010;15(1):215–25.CrossRefPubMed Nonaka Y, Sode K, Ikebukuro K. Screening and improvement of an anti-VEGF DNA aptamer. Molecules. 2010;15(1):215–25.CrossRefPubMed
27.
go back to reference Patwardhan G, Gupta V, Huang J, Gu X, Liu YY. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol. 2010;80(1):72–9.CrossRefPubMedPubMedCentral Patwardhan G, Gupta V, Huang J, Gu X, Liu YY. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol. 2010;80(1):72–9.CrossRefPubMedPubMedCentral
28.
go back to reference Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009;9:6.CrossRefPubMedPubMedCentral Walsh N, Larkin A, Kennedy S, et al. Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol. 2009;9:6.CrossRefPubMedPubMedCentral
29.
go back to reference Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859–76.CrossRefPubMed Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 2006;13(16):1859–76.CrossRefPubMed
30.
go back to reference Tiwari AK, Sodani K, Dai CL, Ashby Jr CR, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12(4):570–94.CrossRefPubMed Tiwari AK, Sodani K, Dai CL, Ashby Jr CR, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol. 2011;12(4):570–94.CrossRefPubMed
31.
go back to reference Xing H, Wang S, Weng D, et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep. 2007;17(1):117–22.PubMed Xing H, Wang S, Weng D, et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep. 2007;17(1):117–22.PubMed
32.
go back to reference Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwan J Obstet Gynecol. 2009;48(3):239–44.CrossRefPubMed Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—a quick review. Taiwan J Obstet Gynecol. 2009;48(3):239–44.CrossRefPubMed
33.
go back to reference Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anti-Cancer Drugs. 2006;17(9):1041–4.CrossRefPubMed Hille S, Rein DT, Riffelmann M, et al. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer. Anti-Cancer Drugs. 2006;17(9):1041–4.CrossRefPubMed
34.
go back to reference Han Z, Feng J, Hong Z, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–94.CrossRefPubMed Han Z, Feng J, Hong Z, et al. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells. Biochem Biophys Res Commun. 2013;435(2):188–94.CrossRefPubMed
35.
36.
go back to reference Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86(2):171–6.CrossRefPubMed Kamazawa S, Kigawa J, Kanamori Y, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol. 2002;86(2):171–6.CrossRefPubMed
37.
go back to reference Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93(1):98–106.CrossRefPubMed Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol. 2004;93(1):98–106.CrossRefPubMed
38.
go back to reference Masanek U, Stammler G, Volm M. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol. 2002;2(1):37–41.CrossRefPubMed Masanek U, Stammler G, Volm M. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol. 2002;2(1):37–41.CrossRefPubMed
39.
go back to reference Jing N. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Exp Opin Investig Drugs. 2000;9(8):1777–85.CrossRef Jing N. Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design. Exp Opin Investig Drugs. 2000;9(8):1777–85.CrossRef
40.
go back to reference Gomez-Marquez J. DNA G-quadruplex: structure, function and human disease. FEBS J. 2010;277(17):3451.CrossRefPubMed Gomez-Marquez J. DNA G-quadruplex: structure, function and human disease. FEBS J. 2010;277(17):3451.CrossRefPubMed
41.
go back to reference Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358–65.CrossRefPubMed Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358–65.CrossRefPubMed
42.
go back to reference Teng Y, Girvan AC, Casson LK, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491–500.CrossRefPubMed Teng Y, Girvan AC, Casson LK, et al. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007;67(21):10491–500.CrossRefPubMed
43.
go back to reference Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate. 2008;68(13):1430–42.CrossRefPubMedPubMedCentral Weerasinghe P, Li Y, Guan Y, Zhang R, Tweardy DJ, Jing N. T40214/PEI complex: a potent therapeutics for prostate cancer that targets STAT3 signaling. Prostate. 2008;68(13):1430–42.CrossRefPubMedPubMedCentral
44.
go back to reference Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12(5):450–8.CrossRefPubMed Tan B, Piwnica-Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol. 2000;12(5):450–8.CrossRefPubMed
45.
go back to reference Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013;2013:872957.CrossRefPubMedPubMedCentral Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J Oncol. 2013;2013:872957.CrossRefPubMedPubMedCentral
46.
go back to reference Park YT, Jeong JY, Lee MJ, et al. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res. 2013;6(1):18.CrossRefPubMedPubMedCentral Park YT, Jeong JY, Lee MJ, et al. MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res. 2013;6(1):18.CrossRefPubMedPubMedCentral
47.
go back to reference Mo QQ, Chen PB, Jin X, et al. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacol Sin. 2013;34(4):541–8.CrossRefPubMedPubMedCentral Mo QQ, Chen PB, Jin X, et al. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacol Sin. 2013;34(4):541–8.CrossRefPubMedPubMedCentral
Metadata
Title
Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells
Authors
Biao Wang
Shuo Li
Xin Meng
Hong Shang
Yifu Guan
Publication date
01-08-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3333-2

Other articles of this Issue 8/2015

Tumor Biology 8/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine